Altimmune Trial Data Selected for AASLD Late-Breaking Presentation
Data from Altimmune’s RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder were selected for a late-breaking oral presentation at AASLD The Liver Meeting 2026.
Related stories
AEHL: trading halted on Nasdaq — volatility pause (10:39 AM ET)
Nasdaq halted trading in AEHL (volatility pause) at 10:39 AM ET.
L impact | EQUITY | Nov 05, 2026, 03:48 PM UTC
Cogent Communications Reports Third-Quarter Revenue of $231.2 Million
Cogent Communications' third-quarter service revenue fell 4.4% year over year, while its net loss narrowed. Revenue was pressured by cancellations of low-margin and non-core custom
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC
Weis Markets Reports Third-Quarter 2026 Revenue of $1.28 Billion, EPS of $0.90
Weis Markets said third-quarter revenue and earnings increased year over year. Higher fuel sales primarily drove sales growth, while higher gross profit increased gross margin; low
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC
Sunoco Reports Third-Quarter Revenue of $18.03 Billion, EPS of $2.07
Sunoco said revenue and earnings increased year over year, primarily reflecting higher segment adjusted EBITDA in fuel distribution, terminals and refining. The largest gains were
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC
Lemonade Reports Third-Quarter Revenue of $336.1M, EPS Loss of $0.56
Revenue rose 73% year over year, while the net loss widened 17%. Growth reflected higher net earned premium from increased gross written premium and a lower reinsurance cession rat
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC
FGC Reports Unauthorized System Access and Personal Data Leak
Brazil’s Fundo Garantidor reports unauthorized access to its system and a leak of personal data.
M impact | EQUITY | Nov 05, 2026, 03:41 PM UTC